Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major

Ítems similars

• Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
  per: Daar, Shahina, et al.
  Publicat: (2009)
• Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
  per: Taher, Ali, et al.
  Publicat: (2009)
• Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
  per: Pennell, Dudley J., et al.
  Publicat: (2011)
• Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
  per: Karami, Hossein, et al.
  Publicat: (2017)
• Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia
  per: Al-Khabori, Murtadha, et al.
  Publicat: (2013)